Change in PD-L1 Expression After Acquiring Resistance to Gefitinib in EGFR-Mutant Non–Small-Cell Lung Cancer

Micro-Abstract Selecting patients for anti-programmed cell death 1 (PD-1) or anti-programmed death ligand 1 (PD-L1) immunotherapy by PD-L1 expression is an important issue in lung cancer. By comparing paired biopsies from patients with EGFR -mutant non–small-cell lung cancer (NSCLC), we found that P...

Full description

Saved in:
Bibliographic Details
Published in:Clinical lung cancer 2016-07, Vol.17 (4), p.263-270.e2
Main Authors: Han, Jae Joon, Kim, Dong-Wan, Koh, Jaemoon, Keam, Bhumsuk, Kim, Tae Min, Jeon, Yoon Kyung, Lee, Se-Hoon, Chung, Doo Hyun, Heo, Dae Seog
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Antineoplastic Agents - therapeutic use
B7-H1 Antigen - genetics
B7-H1 Antigen - metabolism
Biomarkers, Pharmacological - metabolism
Carcinoma, Non-Small-Cell Lung - diagnosis
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - mortality
Epidermal growth factor receptor
Female
Gefitinib
Gene Expression Regulation, Neoplastic - drug effects
Hematology, Oncology and Palliative Medicine
Humans
Male
Middle Aged
NSCLC
Programmed death receptor ligand-1
Pulmonary/Respiratory
Quinazolines - therapeutic use
Receptor, Epidermal Growth Factor - genetics
Survival Analysis
Treatment Outcome
Tumor-infiltrating lymphocytes
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Micro-Abstract Selecting patients for anti-programmed cell death 1 (PD-1) or anti-programmed death ligand 1 (PD-L1) immunotherapy by PD-L1 expression is an important issue in lung cancer. By comparing paired biopsies from patients with EGFR -mutant non–small-cell lung cancer (NSCLC), we found that PD-L1 expression in tumor cells markedly increased in a subset of patients after resistance to gefitinib had developed. In addition, in vitro study results suggest that some resistant mechanisms are involved in PD-L1 overexpression in gefitinib-resistant NSCLC cells. Our findings suggest that repeat biopsy should be considered when using PD-L1 expression as a biomarker after EGFR inhibitor therapy.
ISSN:1525-7304
1938-0690
DOI:10.1016/j.cllc.2015.11.006